To include your compound in the COVID-19 Resource Center, submit it here.

High-dose LT-02 meets ulcerative colitis endpoint

Lipid Therapeutics GmbH (Heidelberg, Germany) said high-dose LT-02 given four times per day met the primary

Read the full 167 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE